Document is current
Any future updates will be listed below
-
Authors
Hatakeyama, Yuki
Kimura, Atsushi Michael
Tsuboguchi, Shintaro
Ratanov, Mikhail
Nakamura, Kosei
Hatakeyama, Masahiro
Nakamura, Yukimi
Watanabe, Masaki
Murakami, Yoshihiro
Saito, Yuko
Murayama, Shigeo
Kasuga, Kensaku
Ikeuchi, Takeshi
Igarashi, Hironaka
Onodera, Osamu
Shimada, Hitoshi https://orcid.org/0000-0002-7139-7178
-
Funding
Funding for this research was provided by:
Japan Society for the Promotion of Science (JP23H02825, JP18K07543)
Japan Science and Technology Corporation (JPMJFR220R)
YUJIN Memorial Award
Splink Co., Ltd.
- License Information
-
More Information
Article History
Received: 23 October 2024
Accepted: 8 December 2024
First Online: 19 December 2024
Declarations
:
: All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Hitoshi Shimada holds patents on compounds related to the present report (JP 5422782/EP 12 884 742.3/CA2894994/HK1208672), and received honoraria for lectures from Eizai Co., Ltd., consultant fee from Splink Co., Ltd., and research fundings from Splink Co., Ltd. and Novartis Pharmaceutical Co., Ltd. All other authors declare that they have no conflicts of interest regarding financial support or relationships.
: The PET study conducted for the present report was approved by the Niigata University Certified Review Board (UMIN 000050731).
: Written informed consent was obtained from the patient.
